CME

Guest: Douglas Rex, MD

In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.

Guest: Douglas Rex, MD

Guest: Aasma Shaukat, MD, MPH

In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.

Guest: Douglas Rex, MD

Guest: Aasma Shaukat, MD, MPH

In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.

Guest: Douglas Rex, MD

Guest: David Johnson, MD

In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.

Guest: Michael J. Mauro, MD

Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the underlying driver of CML. BCR-ABL1 testing is widely used to confirm the clinical diagnosis of CML and to assess response to TKI therapy. The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, dramatically improving patient outcomes. Although most CML patients experience excellent clinical outcomes, some CML patients (20-30%) exhibit an acquired resistance to treatment during the disease course, often requiring second- or third-line therapy. Novel TKIs designed to overcome TKI resistance have shown efficacy in early clinical trials and are offering promise to CML patients who do not respond to any of the multiple therapeutic options currently available.

AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight and address

Host: Yelena Janjigian, MD

The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.

Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Yelena Janjigian, MD

The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.

Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Samuel J. Klempner, MD

The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.

Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Yelena Janjigian, MD

The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.

Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.

Host: Samuel J. Klempner, MD

The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.

Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.